ArticleJournal of gastrointestinal cancer2024

Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.

Munenobu Kashiwa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.